The incidence of myopathy secondary to statin use is approximately 1 in 10,000 patients/year on standard doses, but increases with higher doses or concurrent prescription of drugs such as cyclosporine that can inhibit statin metabolism. Identification of genetic factors that influence an individual’s susceptibility to these complications would improve patient management by identifying those who […]